Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688)

M. J. Overman, L. Adam, K. Raghav, J. Wang, B. Kee, D. Fogelman, C. Eng, E. Vilar, R. Shroff, A. Dasari, R. Wolff, J. Morris, E. Karunasena, T. R. Pisanic, N. Azad, S. Kopetz

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original article, author T. R. Pisanic II's name was incorrectly spelt as 'R. Pisanic II'. This has now been corrected.

Original languageEnglish (US)
Pages (from-to)495
Number of pages1
JournalAnnals of Oncology
Volume30
Issue number3
DOIs
StatePublished - Mar 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688)'. Together they form a unique fingerprint.

Cite this